C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics Inc. is based in WATERTOWN, Mass.
| Revenue (Most Recent Fiscal Year) | $35.95M |
| Net Income (Most Recent Fiscal Year) | $-104.99M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.65 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.07 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -291.74% |
| Net Margin (Trailing 12 Months) | -292.08% |
| Return on Equity (Trailing 12 Months) | -53.83% |
| Return on Assets (Trailing 12 Months) | -33.85% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.81 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.81 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.65 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.18 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.27 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.36 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 97.58M |
| Free Float | 89.06M |
| Market Capitalization | $275.17M |
| Average Volume (Last 20 Days) | 2.34M |
| Beta (Past 60 Months) | 2.85 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.73% |
| Percentage Held By Institutions (Latest 13F Reports) | 78.81% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |